Cuprina Holdings (Cayman) Limited CUPR PHARMA
Company Overview
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.
Recent Developments
- Dec 2025 Revenue of $49.89K (+3.3% YoY); net profit $-4.67M.
- Trailing 12 Months Year-on-year growth — revenue +267.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -4.1%, profit CAGR -109.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -4.12% |
| 1 Year: | 267.40% |
Compounded Profit Growth
| 5 Years: | -109.00% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -95.77% |
| 6 Months: | +5.41% |
| 3 Months: | +24.80% |
| 1 Month: | -6.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -4.1% CAGR over 5 years.
- Earnings shrank at -109.0% CAGR over 5 years.
- Trading 95.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CUPR Cuprina Holdings (Cayman) Limited PHARMA | 3.12 | -2.18 | $16.36M | 0.00% | -85.27% | - | -4.12% | -109.00% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 56.60K | 100.77K | 48.32K | 49.89K |
| Cost of Revenue | - | 36.62K | 64.17K | 51.34K | 50.54K |
| Gross Profit | - | 19.98K | 36.60K | -3.02K | -645 |
| Operating Expenses | - | 1.14M | 1.07M | 1.48M | 4.57M |
| Operating Income | - | -1.12M | -1.03M | -1.48M | -4.57M |
| EBITDA | - | -1.06M | -994.12K | -1.43M | -4.56M |
| Interest Expense | - | 2.02K | 56.59K | 37.21K | 14.72K |
| Pretax Income | - | -1.09M | -1.09M | -1.51M | -4.61M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -1.09M | -1.12M | -1.56M | -4.67M |
| Diluted EPS | -0.20 | -0.42 | -0.41 | -0.57 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.44M | 1.59M | 1.75M | 8.50M |
| Current Assets | - | 1.27M | 1.44M | 1.66M | 7.33M |
| Cash & Equivalents | - | 564.58K | 35.26K | 116.47K | 3.12M |
| Inventory | - | 6.50K | 7.67K | 1.73K | 0 |
| Receivables | - | 41.72K | 50.82K | 26.39K | 18.22K |
| Total Liabilities | - | 3.21M | 4.48M | 6.20M | 3.45M |
| Current Liabilities | - | 3.09M | 4.43M | 6.04M | 3.12M |
| Long Term Debt | - | 43.17K | 21.70K | 163.73K | 126.20K |
| Total Debt | - | 183.63K | 121.82K | 254.79K | 482.72K |
| Total Equity | - | -1.78M | -2.90M | -4.46M | 5.06M |
| Shares Outstanding | - | 2.72M | 2.72M | 2.72M | 2.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.85M | -894.98K | -1.24M | -9.13M |
| Investing Cash Flow | - | -31.28K | -67.98K | -21.88K | -58.23K |
| Financing Cash Flow | - | 1.68M | 433.07K | 1.34M | 12.23M |
| Capital Expenditure | - | -16.05K | -67.98K | -21.88K | -58.23K |
| Free Cash Flow | - | -1.87M | -962.96K | -1.26M | -9.19M |
| Net Change in Cash | - | -202.46K | -529.88K | 83.11K | 3.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 35.3% | 36.3% | -6.3% | -1.3% |
| Operating Margin % | - | -1,987.2% | -1,021.8% | -3,061.7% | -9,154.6% |
| Net Margin % | - | -1,933.8% | -1,111.0% | -3,229.5% | -9,366.8% |
| ROE % | - | 61.5% | 38.6% | 35.0% | -92.4% |
| ROCE % | - | 67.9% | 36.3% | 34.4% | -84.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caitong International Asset Management Co., Ltd | - | 8 | $14 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CUPR
Cuprina Holdings (CUPR) Stock Forum and Discussion - Moomoo
<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxPZ3RIakZSMkg2MzNjQnhrODkxMDRSdXVLTENKV0FPY3B2ZFhHZUExeTlqc25JT2RGa1FiQVNJVkJ4M09OcTZqcDNEMHVENldfTEZ2MHpSbUhWNF9wQnFZUTJRaExsWlg1cTJiaFN5bDF5c0N1WkdWeGdlOVdWYVVsZXhoa1R1SmkyTkg4a2…
Why Did CUPR Stock Surge Over 150% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxON0tjd2NTQXVPNlQxWXVlb0h6RW43SXFUdGUtSzU1dlE5Rmx2SjRoNXp2U1JNNU50Y1lhRy1nalNORkc2bHBVSnVHMHB6QkQ5QWI5cnIySGNKZzZ5QkpTSlp5SlZKMzI4SWp1Nm5TZzJCbmJMSlByQVBlcE9OYU4zWVRPS1hRLXFLZmJ4b1…
Cuprina Holdings Rallies as Traders Revisit Recent FDA Clearance and Nasdaq Compliance Update - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQdVh5bzRPQWZWRmxSd2kyNFpuTHEzQzRsZ2ltQ01sSkw1bEtka0QwWjhFNW9RUGhERTJheGFJMXBNb0VIcHlFd0tzRktwdXhwY2UzdVlIUFlBYmhnb05oZWsxRGZUNnc0Vngwb3ZadE85YlEzWkVaNVB0eUxkOFk3cEEyam9wclBrN082Vk…
Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending - Sahm
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOYkNIY01IV3YwaWg0TGlhUzEtLUFsSW4zeHVxYmNkMm9kdDQxaHRZcE00aTZKUVBqVmxlR0RETmVlc2k2X1R4Z0V0dHlGTElVMFVtbnFoTnlwVlBReUI0M1cyZktDYzBXODlSTGVOSkZkRUJCWmQ4Z3I5UHlra2J6YzdQVUg5VWpmcmlsSV…
What's Going On With Cuprina Stock Monday? - Cuprina Holdings (Cayman) (NASDAQ:CUPR) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPdXF3c2xFb1FrckMyc3BJSk9aQVpJelpMRU1VRkFRTjdqTDZyeTFHOWRmcjRFNHJud0NaakExTUdlU0RkTUdlcmZqU0RHZEdrcm4zaFZ1eGdocmpkbUNraXhqSzB2WU8xUEFBTDk2Q3RoUmVLcHowb2JKelFGa0VQRGxBN3E3dGl3NzZ5eD…
CUPR Stock Ignites As Traders Pile Into Momentum Spike - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOajJ2UGZjS0V0eHhDdFBDZ0hRdkV2am1fV2UtQXJvOTItVGd0TVc0ajVDdW5aZ0pwOTdqSmRlSGQ5LTU0bXF0WGFyd1h5MzgzdHFkT1EyeFY1OFpPbXJHRHZZSFN0QVBtdExabmFIaTJMZTJjMTFBSjZ1cUNKcUF4RUlfOW1QWDhCR0tLQQ…
CUPR — Frequently Asked Questions
What is the current share price of Cuprina Holdings (Cayman) Limited (CUPR)?
As of 2026-09-19 21:16 PDT, Cuprina Holdings (Cayman) Limited (CUPR) trades at $3.12 on NasdaqCM. Its 52-week range is $1.96 to $75.20.
What is the market capitalisation of CUPR?
Cuprina Holdings (Cayman) Limited (CUPR) has a market capitalisation of $16.36M on NasdaqCM.
What is the P/E ratio of CUPR?
CUPR trades at a trailing price-to-earnings (P/E) ratio of -2.18. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.21.
Is CUPR a good stock to buy?
This page provides a data-driven analysis of Cuprina Holdings (Cayman) Limited (CUPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.